Urigen N.A. and S. Grant Mulholland, M.D. to Collaborate on URG301 Drug Development Project for Overactive Bladder
6/13/2007 2:03:01 PM
BURLINGAME, Calif.--(BUSINESS WIRE)--Urigen N.A., Inc. (VLTS.PK), a specialty pharmaceutical company focused on the development of treatments for urological disorders, announces that S. Grant Mulholland, M.D. has accepted the role of Lead Consultant for its URG301 drug development program targeting acute urgency associated with overactive bladder in women.
Over the past 30 years, Dr. Mulholland has achieved international recognition for his interest and expertise in urologic oncology and general urology. Dr. Mulholland is a member of numerous urologic, oncologic and surgical organizations, including the past President of the Philadelphia Urologic and Mid-Atlantic Section of the American Urological Association. Dr. Mulholland has also authored over 180 articles, chapters and books.
comments powered by